Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment

Martín, Víctor; Grenho, Liliana; Fernandes, María Helena; Gomes, Pedro S.

doi:10.1007/s00774-023-01428-9

Cited by 3 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, sarecycline is a viable long-term treatment option for patients who have partial or complete responses to doxycycline, but who have met or exceeded the recommended duration of therapy. Aside from its antimicrobial effects, sarecycline affects the Wnt and Hedgehog molecular pathways, both of which have been implicated in the pathogenesis of acne [ 10 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia

Poplausky,

Young,

Dubin

et al. 2023

Cureus

View full text Add to dashboard Cite

Dasatinib is a second-generation tyrosine inhibitor that is used for the treatment of patients with chronic myeloid leukemia (CML). It can cause a myriad of skin toxicities, including pruritis, pigmentary abnormalities of hair and skin, and maculopapular rashes. Rarely, it can be associated with acneiform eruptions, which are typically treated with doxycycline. However, doxycycline may not be an ideal therapy, especially for long-term use, due to the risk of gut flora disruption, antimicrobial resistance, and side effects. We present a case of a CML patient who developed an acneiform eruption associated with dasatinib and was successfully treated with sarecycline, a narrow-spectrum tetracycline. Given its targeted spectrum of activity, sarecycline has a lower risk of antimicrobial resistance and an improved safety profile compared to first- and second-generation tetracyclines such as doxycycline. As acneiform drug eruptions can have a significant impact on a patient’s quality of life, effective management by dermatologists is paramount. Sarecycline may be a suitable treatment with a favorable safety profile, making it an appropriate choice for patients, especially those who require long-term therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia

Poplausky,

Young,

Dubin

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Consequently, the investigation of TCs’ potential modulatory effects on bone tissue has gained attention. While some studies have explored the potential effects of individual TCs on osteogenic differentiation—such as minocycline, doxycycline [ 26 ], and sarecycline [ 33 ]—a comparative evaluation within the same experimental settings is still lacking. Additionally, the characterization of the underlying signaling pathways responsible for the observed effects remains unexplored.…”

Section: Discussionmentioning

confidence: 99%

Unveiling the Osteogenic Potential of Tetracyclines: A Comparative Study in Human Mesenchymal Stem Cells

Martin,

Bettencourt,

Santos

et al. 2023

Cells

Self Cite

View full text Add to dashboard Cite

Tetracyclines (TCs) are a class of broad-spectrum antibiotics with diverse pharmacotherapeutic properties due to their various functional groups being attached to a common core structure. Beyond their antibacterial activity, TCs trigger pleiotropic effects on eukaryotic cells, including anti-inflammatory and potentially osteogenic capabilities. Consequently, TCs hold promise for repurposing in various clinical applications, including bone-related conditions. This study presents the first comprehensive comparison of the in vitro osteogenic potential of four TCs—tetracycline, doxycycline, minocycline, and sarecycline, within human mesenchymal stem cells. Cultures were characterized for metabolic activity, cell morphology and cytoskeleton organization, osteogenic gene expression, alkaline phosphatase (ALP) activity, and the activation of relevant signaling pathways. TCs stimulated actin remodeling processes, inducing morphological shifts consistent with osteogenic differentiation. Osteogenic gene expression and ALP activity supported the osteoinduction by TCs, demonstrating significant increases in ALP levels and the upregulation of RUNX2, SP7, and SPARC genes. Minocycline and sarecycline exhibited the most potent osteogenic induction, comparable to conventional osteogenic inducers. Signaling pathway analysis revealed that tetracycline and doxycycline activate the Wnt pathway, while minocycline and sarecycline upregulated Hedgehog signaling. Overall, the present findings suggest that TCs promote osteogenic differentiation through distinct pathways, making them promising candidates for targeted therapy in specific bone-related disorders.

show abstract

Reviewing particulate delivery systems loaded with repurposed tetracyclines – From micro to nanoparticles

Martin,

Francisca Bettencourt,

Santos

et al. 2024

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment

Cited by 3 publications

References 47 publications

Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia

Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia

Unveiling the Osteogenic Potential of Tetracyclines: A Comparative Study in Human Mesenchymal Stem Cells

Reviewing particulate delivery systems loaded with repurposed tetracyclines – From micro to nanoparticles

Contact Info

Product

Resources

About